ONTOLOGY REPORT - ANNOTATIONS
| Term: | thalidomide |
|
| Accession: | CHEBI:9513
|
browse the term
|
| Definition: | A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group. |
| Synonyms: | exact_synonym: | 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione |
| | related_synonym: | 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)isoindoline; 2,6-dioxo-3-phthalimidopiperidine; 3-phthalimidoglutarimide; C13H10N2O4; Distaval; InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17); InChIKey=UEJJHQNACJXSKW-UHFFFAOYSA-N; K-17; N-(2,6-dioxo-3-piperidyl)phthalimide; N-Phthalyl-glutaminsaeure-imid; N-phthaloylglutamimide; N-phthalylglutamic acid imide; O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1; Sedalis; Softenon; Talimol; alpha-(N-phthalimido)glutarimide; alpha-N-phthalylglutaramide; alpha-phthalimidoglutarimide; talidomida; thalidomidum |
| | xref_casrn: | 50-35-1 |
| | xref: | ChEMBL:105028 "ChEMBL COMPOUND"; ChemIDplus:50-35-1 "CAS Registry Number"; CiteXplore:12724820 "PubMed citation"; CiteXplore:18925849 "PubMed citation"; CiteXplore:21207098 "PubMed citation"; CiteXplore:2694291 "PubMed citation"; CiteXplore:8469046 "PubMed citation"; DrugBank:DB01041 "DrugBank"; KEGG COMPOUND:50-35-1 "CAS Registry Number"; KEGG COMPOUND:C07910 "KEGG COMPOUND"; KEGG DRUG:D00754 "KEGG DRUG" |
| | xref_mesh: | MESH:D013792 |
| | xref: | NIST Chemistry WebBook:50-35-1 "CAS Registry Number"; Patent:GB768821 "Patent"; Reaxys:30233 "Reaxys Registry Number"; Wikipedia:Thalidomide "Wikipedia" |
|
|
thalidomide
|
| G |
Abca1 |
ATP-binding cassette, subfamily A (ABC1), member 1 |
|
increases response to substance |
ISO |
5 |
70,493,357 |
70,583,729 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
decreases expression |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
decreases expression |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
decreases activity |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
|
increases activity |
EXP |
4 |
21,829,489 |
21,912,239 |
RGD:6480464 |
CTD |
| G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
|
increases expression |
EXP |
4 |
21,829,489 |
21,912,239 |
RGD:6480464 |
CTD |
| G |
Acp5 |
acid phosphatase 5, tartrate resistant |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
decreases phosphorylation |
ISO |
6 |
137,640,482 |
137,657,552 |
RGD:6480464 |
CTD |
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
increases phosphorylation |
ISO |
6 |
137,640,482 |
137,657,552 |
RGD:6480464 |
CTD |
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
decreases activity |
ISO |
6 |
137,640,482 |
137,657,552 |
RGD:6480464 |
CTD |
| G |
Angpt2 |
angiopoietin 2 |
|
affects expression |
ISO |
16 |
75,891,757 |
75,942,255 |
RGD:6480464 |
CTD |
| G |
Anxa2 |
annexin A2 |
|
decreases expression |
ISO |
8 |
73,897,618 |
73,934,041 |
RGD:6480464 |
CTD |
| G |
Atf3 |
activating transcription factor 3 |
|
increases expression |
ISO |
13 |
107,191,622 |
107,223,850 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
increases expression |
EXP |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
decreases expression |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
decreases expression |
ISO |
3 |
143,129,087 |
143,180,199 |
RGD:6480464 |
CTD |
| G |
Bdkrb1 |
bradykinin receptor B1 |
|
multiple interactions |
ISO |
6 |
129,760,129 |
129,762,545 |
RGD:6480464 |
CTD |
| G |
Becn1 |
beclin 1, autophagy related |
|
multiple interactions |
ISO |
10 |
90,317,957 |
90,333,329 |
RGD:6480464 |
CTD |
| G |
Bub1b |
BUB1 mitotic checkpoint serine/threonine kinase B |
|
multiple interactions |
ISO |
3 |
105,063,018 |
105,116,145 |
RGD:6480464 |
CTD |
| G |
C3 |
complement component 3 |
|
decreases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
decreases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases expression |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp8 |
caspase 8 |
|
increases cleavage |
ISO |
9 |
57,389,353 |
57,437,803 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
decreases activity |
ISO |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
multiple interactions |
ISO |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
decreases expression |
ISO |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccl3 |
chemokine (C-C motif) ligand 3 |
|
increases expression |
EXP |
10 |
71,744,559 |
71,746,109 |
RGD:6480464 |
CTD |
| G |
Ccna2 |
cyclin A2 |
|
multiple interactions |
ISO |
2 |
123,062,752 |
123,069,085 |
RGD:6480464 |
CTD |
| G |
Ccnb1 |
cyclin B1 |
|
multiple interactions |
ISO |
2 |
31,574,600 |
31,581,784 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
decreases expression |
ISO |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Cdc20 |
cell division cycle 20 |
|
multiple interactions |
ISO |
5 |
138,913,180 |
138,916,744 |
RGD:6480464 |
CTD |
| G |
Cdk1 |
cyclin-dependent kinase 1 |
|
multiple interactions |
ISO |
20 |
20,018,044 |
20,044,030 |
RGD:6480464 |
CTD |
| G |
Cenpa |
centromere protein A |
|
multiple interactions |
ISO |
6 |
25,686,603 |
25,693,840 |
RGD:6480464 |
CTD |
| G |
Cenpf |
centromere protein F |
|
multiple interactions |
ISO |
13 |
105,920,242 |
105,965,655 |
RGD:6480464 |
CTD |
| G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
|
decreases expression |
ISO |
9 |
57,309,836 |
57,356,635 |
RGD:6480464 |
CTD |
| G |
Chuk |
conserved helix-loop-helix ubiquitous kinase |
|
multiple interactions |
EXP |
1 |
249,122,845 |
249,158,369 |
RGD:6480464 |
CTD |
| G |
Col1a2 |
collagen, type I, alpha 2 |
|
multiple interactions |
EXP |
4 |
29,393,645 |
29,428,572 |
RGD:6480464 |
CTD |
| G |
Crebrf |
CREB3 regulatory factor |
|
increases expression |
ISO |
10 |
16,665,420 |
16,723,929 |
RGD:6480464 |
CTD |
| G |
Crp |
C-reactive protein, pentraxin-related |
|
decreases expression |
ISO |
13 |
88,702,243 |
88,703,153 |
RGD:6480464 |
CTD |
| G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
|
decreases activity |
ISO |
10 |
39,665,850 |
39,667,831 |
RGD:6480464 |
CTD |
| G |
Csf3 |
colony stimulating factor 3 (granulocyte) |
|
decreases activity |
ISO |
10 |
87,473,990 |
87,476,365 |
RGD:6480464 |
CTD |
| G |
Cxcl10 |
chemokine (C-X-C motif) ligand 10 |
|
increases expression |
ISO |
14 |
17,265,986 |
17,268,183 |
RGD:6480464 |
CTD |
| G |
Cxcr1 |
chemokine (C-X-C motif) receptor 1 |
|
decreases expression |
ISO |
9 |
73,510,488 |
73,511,537 |
RGD:6480464 |
CTD |
| G |
Cxcr2 |
chemokine (C-X-C motif) receptor 2 |
|
decreases expression |
ISO |
9 |
73,470,943 |
73,477,315 |
RGD:6480464 |
CTD |
| G |
Cycs |
cytochrome c, somatic |
|
increases expression |
ISO |
4 |
78,825,878 |
78,827,978 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
increases hydroxylation |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
|
multiple interactions |
ISO |
12 |
17,164,384 |
17,204,589 |
RGD:6480464 |
CTD |
| G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
|
increases hydroxylation |
ISO |
12 |
17,164,384 |
17,204,589 |
RGD:6480464 |
CTD |
| G |
Ddit3 |
DNA-damage inducible transcript 3 |
|
increases expression |
ISO |
7 |
67,247,749 |
67,252,571 |
RGD:6480464 |
CTD |
| G |
Des |
desmin |
|
multiple interactions |
EXP |
9 |
74,637,783 |
74,645,499 |
RGD:6480464 |
CTD |
| G |
Dnajb1 |
DnaJ (Hsp40) homolog, subfamily B, member 1 |
|
increases expression |
ISO |
19 |
26,213,739 |
26,217,480 |
RGD:6480464 |
CTD |
| G |
Dnajb4 |
DnaJ (Hsp40) homolog, subfamily B, member 4 |
|
increases expression |
ISO |
2 |
250,663,022 |
250,685,242 |
RGD:6480464 |
CTD |
| G |
Dnajb9 |
DnaJ (Hsp40) homolog, subfamily B, member 9 |
|
increases expression |
ISO |
6 |
63,583,033 |
63,587,247 |
RGD:6480464 |
CTD |
| G |
Dusp1 |
dual specificity phosphatase 1 |
|
increases expression |
ISO |
10 |
16,942,913 |
16,945,696 |
RGD:6480464 |
CTD |
| G |
Dusp10 |
dual specificity phosphatase 10 |
|
increases expression |
ISO |
13 |
100,022,421 |
100,059,539 |
RGD:6480464 |
CTD |
| G |
Dusp8 |
dual specificity phosphatase 8 |
|
increases expression |
ISO |
1 |
202,215,086 |
202,229,746 |
RGD:6480464 |
CTD |
| G |
Eif4e |
eukaryotic translation initiation factor 4E |
|
decreases expression |
EXP |
2 |
236,072,748 |
236,104,714 |
RGD:6480464 |
CTD |
| G |
Elane |
elastase, neutrophil expressed |
|
multiple interactions |
ISO |
7 |
11,329,642 |
11,331,490 |
RGD:6480464 |
CTD |
| G |
F2r |
coagulation factor II (thrombin) receptor |
|
decreases expression |
ISO |
2 |
25,985,800 |
25,989,072 |
RGD:6480464 |
CTD |
| G |
Fas |
Fas (TNF receptor superfamily, member 6) |
|
decreases expression |
ISO |
1 |
238,259,443 |
238,274,745 |
RGD:6480464 |
CTD |
| G |
Fas |
Fas (TNF receptor superfamily, member 6) |
|
increases expression |
EXP |
1 |
238,259,443 |
238,274,745 |
RGD:6480464 |
CTD |
| G |
Faslg |
Fas ligand (TNF superfamily, member 6) |
|
multiple interactions |
ISO |
13 |
77,472,950 |
77,480,210 |
RGD:6480464 |
CTD |
| G |
Faslg |
Fas ligand (TNF superfamily, member 6) |
|
decreases expression |
ISO |
13 |
77,472,950 |
77,480,210 |
RGD:6480464 |
CTD |
| G |
Fen1 |
flap structure-specific endonuclease 1 |
|
multiple interactions |
ISO |
1 |
212,688,118 |
212,692,486 |
RGD:6480464 |
CTD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
increases response to substance |
ISO |
2 |
123,893,314 |
123,947,136 |
RGD:6480464 |
CTD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
affects expression |
ISO |
2 |
123,893,314 |
123,947,136 |
RGD:6480464 |
CTD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
affects secretion |
ISO |
2 |
123,893,314 |
123,947,136 |
RGD:6480464 |
CTD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
multiple interactions |
ISO |
2 |
123,893,314 |
123,947,136 |
RGD:6480464 |
CTD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
decreases activity |
ISO |
2 |
123,893,314 |
123,947,136 |
RGD:6480464 |
CTD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
decreases expression |
ISO |
2 |
123,893,314 |
123,947,136 |
RGD:6480464 |
CTD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
multiple interactions |
EXP |
2 |
123,893,314 |
123,947,136 |
RGD:6480464 |
CTD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
decreases expression |
ISO |
2 |
123,893,314 |
123,947,136 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
ISO |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fosb |
FBJ osteosarcoma oncogene B |
|
increases expression |
ISO |
1 |
78,668,497 |
78,673,330 |
RGD:6480464 |
CTD |
| G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
|
multiple interactions |
ISO |
7 |
10,289,073 |
10,291,102 |
RGD:6480464 |
CTD |
| G |
Gata3 |
GATA binding protein 3 |
|
increases expression |
EXP |
17 |
79,991,587 |
80,011,574 |
RGD:6480464 |
CTD |
| G |
Gpx1 |
glutathione peroxidase 1 |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Herpud1 |
homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1 |
|
increases expression |
ISO |
19 |
11,036,567 |
11,046,914 |
RGD:6480464 |
CTD |
| G |
Hgf |
hepatocyte growth factor |
|
affects expression |
ISO |
4 |
14,864,357 |
14,932,513 |
RGD:6480464 |
CTD |
| G |
Hgf |
hepatocyte growth factor |
|
decreases activity |
ISO |
4 |
14,864,357 |
14,932,513 |
RGD:6480464 |
CTD |
| G |
Hgf |
hepatocyte growth factor |
|
affects secretion |
ISO |
4 |
14,864,357 |
14,932,513 |
RGD:6480464 |
CTD |
| G |
Hsph1 |
heat shock 105/110 protein 1 |
|
increases expression |
ISO |
12 |
5,794,645 |
5,811,453 |
RGD:6480464 |
CTD |
| G |
Icam1 |
intercellular adhesion molecule 1 |
|
increases response to substance |
ISO |
8 |
20,040,177 |
20,051,939 |
RGD:6480464 |
CTD |
| G |
Icam1 |
intercellular adhesion molecule 1 |
|
decreases expression |
EXP |
8 |
20,040,177 |
20,051,939 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
multiple interactions |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
affects expression |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
increases expression |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
increases expression |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
multiple interactions |
EXP |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
decreases expression |
EXP |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Igf1 |
insulin-like growth factor 1 |
|
affects expression |
ISO |
7 |
24,531,669 |
24,605,742 |
RGD:6480464 |
CTD |
| G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
|
affects expression |
ISO |
14 |
87,959,153 |
87,967,085 |
RGD:6480464 |
CTD |
| G |
Il10 |
interleukin 10 |
|
affects expression |
ISO |
13 |
43,953,900 |
43,957,766 |
RGD:6480464 |
CTD |
| G |
Il10 |
interleukin 10 |
|
decreases expression |
ISO |
13 |
43,953,900 |
43,957,766 |
RGD:6480464 |
CTD |
| G |
Il12a |
interleukin 12A |
|
multiple interactions |
ISO |
2 |
158,710,261 |
158,717,689 |
RGD:6480464 |
CTD |
| G |
Il12b |
interleukin 12B |
|
multiple interactions |
ISO |
10 |
29,558,955 |
29,568,331 |
RGD:6480464 |
CTD |
| G |
Il12b |
interleukin 12B |
|
multiple interactions |
ISO |
10 |
29,558,955 |
29,568,331 |
RGD:6480464 |
CTD |
| G |
Il18 |
interleukin 18 |
|
increases expression |
ISO |
8 |
53,936,584 |
53,943,228 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
decreases expression |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
EXP |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1r1 |
interleukin 1 receptor, type I |
|
decreases expression |
ISO |
9 |
39,434,910 |
39,473,552 |
RGD:6480464 |
CTD |
| G |
Il1rn |
interleukin 1 receptor antagonist |
|
multiple interactions |
ISO |
3 |
2,607,800 |
2,613,216 |
RGD:6480464 |
CTD |
| G |
Il2 |
interleukin 2 |
|
multiple interactions |
ISO |
2 |
123,655,005 |
123,659,709 |
RGD:6480464 |
CTD |
| G |
Il2 |
interleukin 2 |
|
decreases expression |
ISO |
2 |
123,655,005 |
123,659,709 |
RGD:6480464 |
CTD |
| G |
Il2 |
interleukin 2 |
|
multiple interactions |
EXP |
2 |
123,655,005 |
123,659,709 |
RGD:6480464 |
CTD |
| G |
Il4 |
interleukin 4 |
|
increases expression |
EXP |
10 |
39,074,582 |
39,080,134 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
decreases secretion |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
decreases activity |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
EXP |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6st |
interleukin 6 signal transducer |
|
decreases expression |
ISO |
2 |
43,806,301 |
43,842,365 |
RGD:6480464 |
CTD |
| G |
Ing3 |
inhibitor of growth family, member 3 |
|
increases expression |
ISO |
4 |
48,255,445 |
48,281,131 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
increases expression |
ISO |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Kdr |
kinase insert domain receptor |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Kif2c |
kinesin family member 2C |
|
multiple interactions |
ISO |
5 |
137,473,698 |
137,498,974 |
RGD:6480464 |
CTD |
| G |
Lats2 |
large tumor suppressor 2 |
|
increases expression |
ISO |
15 |
36,720,000 |
36,761,065 |
RGD:6480464 |
CTD |
| G |
Ltf |
lactotransferrin |
|
multiple interactions |
ISO |
8 |
115,417,764 |
115,440,609 |
RGD:6480464 |
CTD |
| G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
|
multiple interactions |
ISO |
19 |
51,847,187 |
51,854,858 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
increases phosphorylation |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk14 |
mitogen activated protein kinase 14 |
|
increases phosphorylation |
ISO |
20 |
6,939,249 |
7,000,378 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
increases phosphorylation |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mcl1 |
myeloid cell leukemia sequence 1 |
|
decreases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Mcm5 |
minichromosome maintenance complex component 5 |
|
multiple interactions |
ISO |
19 |
13,978,940 |
14,000,641 |
RGD:6480464 |
CTD |
| G |
Mki67 |
antigen identified by monoclonal antibody Ki-67 |
|
multiple interactions |
ISO |
1 |
195,310,027 |
195,336,224 |
RGD:6480464 |
CTD |
| G |
Mmp2 |
matrix metallopeptidase 2 |
|
multiple interactions |
ISO |
19 |
15,246,036 |
15,275,061 |
RGD:6480464 |
CTD |
| G |
Mmp2 |
matrix metallopeptidase 2 |
|
decreases expression |
ISO |
19 |
15,246,036 |
15,275,061 |
RGD:6480464 |
CTD |
| G |
Mmp2 |
matrix metallopeptidase 2 |
|
decreases expression |
ISO |
19 |
15,246,036 |
15,275,061 |
RGD:6480464 |
CTD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
decreases expression |
ISO |
3 |
155,985,473 |
155,993,433 |
RGD:6480464 |
CTD |
| G |
Mpo |
myeloperoxidase |
|
multiple interactions |
ISO |
10 |
76,085,872 |
76,097,012 |
RGD:6480464 |
CTD |
| G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
|
multiple interactions |
ISO |
2 |
233,091,013 |
233,187,501 |
RGD:6480464 |
CTD |
| G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
|
decreases expression |
EXP |
2 |
233,091,013 |
233,187,501 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
multiple interactions |
ISO |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
multiple interactions |
ISO |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
multiple interactions |
EXP |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
multiple interactions |
EXP |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
increases expression |
EXP |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nppb |
natriuretic peptide B |
|
multiple interactions |
ISO |
5 |
165,062,348 |
165,063,650 |
RGD:6480464 |
CTD |
| G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
|
increases expression |
ISO |
7 |
140,012,807 |
140,020,590 |
RGD:6480464 |
CTD |
| G |
Nr4a2 |
nuclear receptor subfamily 4, group A, member 2 |
|
increases expression |
ISO |
3 |
38,866,205 |
38,871,678 |
RGD:6480464 |
CTD |
| G |
Nrp1 |
neuropilin 1 |
|
multiple interactions |
ISO |
19 |
58,332,004 |
58,487,686 |
RGD:6480464 |
CTD |
| G |
Nrp2 |
neuropilin 2 |
|
multiple interactions |
ISO |
9 |
61,348,529 |
61,460,457 |
RGD:6480464 |
CTD |
| G |
Nusap1 |
nucleolar and spindle associated protein 1 |
|
multiple interactions |
ISO |
3 |
106,134,200 |
106,165,155 |
RGD:6480464 |
CTD |
| G |
Ocln |
occludin |
|
multiple interactions |
ISO |
2 |
31,317,090 |
31,367,485 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
multiple interactions |
ISO |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
increases cleavage |
ISO |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Pecam1 |
platelet/endothelial cell adhesion molecule 1 |
|
decreases expression |
EXP |
10 |
96,056,220 |
96,057,232 |
RGD:6480464 |
CTD |
| G |
Pim1 |
pim-1 oncogene |
|
decreases expression |
ISO |
20 |
7,817,403 |
7,821,800 |
RGD:6480464 |
CTD |
| G |
Plau |
plasminogen activator, urokinase |
|
decreases expression |
ISO |
15 |
3,680,072 |
3,686,232 |
RGD:6480464 |
CTD |
| G |
Plaur |
plasminogen activator, urokinase receptor |
|
decreases expression |
ISO |
1 |
79,708,646 |
79,712,881 |
RGD:6480464 |
CTD |
| G |
Plaur |
plasminogen activator, urokinase receptor |
|
multiple interactions |
ISO |
1 |
79,708,646 |
79,712,881 |
RGD:6480464 |
CTD |
| G |
Potef |
POTE ankyrin domain family, member F |
|
multiple interactions |
EXP |
18 |
24,420,779 |
24,422,284 |
RGD:6480464 |
CTD |
| G |
Potef |
POTE ankyrin domain family, member F |
|
decreases expression |
EXP |
18 |
24,420,779 |
24,422,284 |
RGD:6480464 |
CTD |
| G |
Potef |
POTE ankyrin domain family, member F |
|
multiple interactions |
EXP |
18 |
24,420,779 |
24,422,284 |
RGD:6480464 |
CTD |
| G |
Ppard |
peroxisome proliferator-activated receptor delta |
|
increases response to substance |
ISO |
20 |
6,479,108 |
6,544,255 |
RGD:6480464 |
CTD |
| G |
Ppp1r15a |
protein phosphatase 1, regulatory subunit 15A |
|
increases expression |
ISO |
1 |
95,994,023 |
95,997,080 |
RGD:6480464 |
CTD |
| G |
Prf1 |
perforin 1 (pore forming protein) |
|
increases expression |
ISO |
20 |
28,658,367 |
28,663,877 |
RGD:6480464 |
CTD |
| G |
Pten |
phosphatase and tensin homolog |
|
increases expression |
ISO |
1 |
236,771,027 |
236,837,261 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
increases degradation |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
decreases expression |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
EXP |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
EXP |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
EXP |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
decreases expression |
EXP |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
EXP |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
decreases expression |
EXP |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
decreases expression |
EXP |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Relb |
v-rel reticuloendotheliosis viral oncogene homolog B |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Rfc3 |
replication factor C (activator 1) 3 |
|
multiple interactions |
ISO |
12 |
3,224,493 |
3,235,256 |
RGD:6480464 |
CTD |
| G |
Rrm2 |
ribonucleotide reductase M2 |
|
multiple interactions |
ISO |
6 |
42,350,541 |
42,356,748 |
RGD:6480464 |
CTD |
| G |
Sell |
selectin L |
|
decreases expression |
ISO |
13 |
79,827,342 |
79,845,296 |
RGD:6480464 |
CTD |
| G |
Serpinb2 |
serpin peptidase inhibitor, clade B (ovalbumin), member 2 |
|
increases response to substance |
ISO |
13 |
13,632,596 |
13,641,605 |
RGD:6480464 |
CTD |
| G |
Slc12a6 |
solute carrier family 12, member 6 |
|
increases response to substance |
ISO |
3 |
98,110,547 |
98,212,242 |
RGD:6480464 |
CTD |
| G |
Smpd2 |
sphingomyelin phosphodiesterase 2, neutral membrane |
|
multiple interactions |
ISO |
20 |
45,448,774 |
45,451,887 |
RGD:6480464 |
CTD |
| G |
Snx16 |
sorting nexin 16 |
|
increases expression |
ISO |
2 |
93,274,839 |
93,296,194 |
RGD:6480464 |
CTD |
| G |
Sod1 |
superoxide dismutase 1, soluble |
|
multiple interactions |
ISO |
11 |
29,810,766 |
29,816,342 |
RGD:6480464 |
CTD |
| G |
Sod1 |
superoxide dismutase 1, soluble |
|
multiple interactions |
EXP |
11 |
29,810,766 |
29,816,342 |
RGD:6480464 |
CTD |
| G |
Sp1 |
Sp1 transcription factor |
|
decreases activity |
ISO |
7 |
141,164,180 |
141,194,509 |
RGD:6480464 |
CTD |
| G |
Spag5 |
sperm associated antigen 5 |
|
multiple interactions |
ISO |
10 |
64,313,146 |
64,330,975 |
RGD:6480464 |
CTD |
| G |
Stat3 |
signal transducer and activator of transcription 3 (acute-phase response factor) |
|
decreases phosphorylation |
ISO |
10 |
89,821,078 |
89,872,970 |
RGD:6480464 |
CTD |
| G |
Stat3 |
signal transducer and activator of transcription 3 (acute-phase response factor) |
|
multiple interactions |
ISO |
10 |
89,821,078 |
89,872,970 |
RGD:6480464 |
CTD |
| G |
Stat3 |
signal transducer and activator of transcription 3 (acute-phase response factor) |
|
multiple interactions |
ISO |
10 |
89,821,078 |
89,872,970 |
RGD:6480464 |
CTD |
| G |
Tek |
TEK tyrosine kinase, endothelial |
|
decreases expression |
ISO |
5 |
115,047,195 |
115,196,172 |
RGD:6480464 |
CTD |
| G |
Tgfb1 |
transforming growth factor, beta 1 |
|
multiple interactions |
ISO |
1 |
80,894,705 |
80,911,020 |
RGD:6480464 |
CTD |
| G |
Tgfb1 |
transforming growth factor, beta 1 |
|
multiple interactions |
ISO |
1 |
80,894,705 |
80,911,020 |
RGD:6480464 |
CTD |
| G |
Tgfb1 |
transforming growth factor, beta 1 |
|
multiple interactions |
EXP |
1 |
80,894,705 |
80,911,020 |
RGD:6480464 |
CTD |
| G |
Tgfb1 |
transforming growth factor, beta 1 |
|
multiple interactions |
EXP |
1 |
80,894,705 |
80,911,020 |
RGD:6480464 |
CTD |
| G |
Tgfb1 |
transforming growth factor, beta 1 |
|
decreases expression |
EXP |
1 |
80,894,705 |
80,911,020 |
RGD:6480464 |
CTD |
| G |
Tgfb1 |
transforming growth factor, beta 1 |
|
multiple interactions |
EXP |
1 |
80,894,705 |
80,911,020 |
RGD:6480464 |
CTD |
| G |
Tgfb1 |
transforming growth factor, beta 1 |
|
decreases expression |
EXP |
1 |
80,894,705 |
80,911,020 |
RGD:6480464 |
CTD |
| G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
|
multiple interactions |
EXP |
X |
12,542,496 |
12,547,094 |
RGD:6480464 |
CTD |
| G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
|
multiple interactions |
EXP |
X |
12,542,496 |
12,547,094 |
RGD:6480464 |
CTD |
| G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
|
multiple interactions |
EXP |
10 |
108,310,473 |
108,358,821 |
RGD:6480464 |
CTD |
| G |
Tjp1 |
tight junction protein 1 |
|
multiple interactions |
ISO |
1 |
119,684,774 |
119,750,532 |
RGD:6480464 |
CTD |
| G |
Tmpo |
thymopoietin |
|
multiple interactions |
ISO |
7 |
28,086,576 |
28,111,800 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
decreases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
decreases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
decreases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
decreases expression |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases expression |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases degradation |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
decreases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
decreases expression |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
decreases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
decreases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
decreases expression |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
decreases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
decreases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
decreases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
decreases expression |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnfrsf10b |
tumor necrosis factor receptor superfamily, member 10b |
|
decreases expression |
ISO |
15 |
50,138,439 |
50,163,254 |
RGD:6480464 |
CTD |
| G |
Tnfrsf1a |
tumor necrosis factor receptor superfamily, member 1a |
|
decreases expression |
ISO |
4 |
162,172,563 |
162,185,252 |
RGD:6480464 |
CTD |
| G |
Tnfrsf1a |
tumor necrosis factor receptor superfamily, member 1a |
|
decreases expression |
ISO |
4 |
162,172,563 |
162,185,252 |
RGD:6480464 |
CTD |
| G |
Tnfrsf1b |
tumor necrosis factor receptor superfamily, member 1b |
|
decreases expression |
ISO |
5 |
163,666,541 |
163,697,484 |
RGD:6480464 |
CTD |
| G |
Tnfsf10 |
tumor necrosis factor (ligand) superfamily, member 10 |
|
decreases expression |
ISO |
2 |
113,204,303 |
113,221,550 |
RGD:6480464 |
CTD |
| G |
Tnfsf11 |
tumor necrosis factor (ligand) superfamily, member 11 |
|
multiple interactions |
ISO |
15 |
59,397,837 |
59,428,014 |
RGD:6480464 |
CTD |
| G |
Top2a |
topoisomerase (DNA) II alpha |
|
multiple interactions |
ISO |
10 |
87,771,337 |
87,800,960 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
increases expression |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Trib3 |
tribbles homolog 3 (Drosophila) |
|
increases expression |
ISO |
3 |
142,664,641 |
142,670,135 |
RGD:6480464 |
CTD |
| G |
Ttk |
Ttk protein kinase |
|
multiple interactions |
ISO |
8 |
88,906,665 |
88,944,613 |
RGD:6480464 |
CTD |
| G |
Ube2c |
ubiquitin-conjugating enzyme E2C |
|
multiple interactions |
ISO |
3 |
155,800,357 |
155,802,757 |
RGD:6480464 |
CTD |
| G |
Vcam1 |
vascular cell adhesion molecule 1 |
|
decreases expression |
EXP |
2 |
212,277,654 |
212,297,376 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
affects expression |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
affects secretion |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
decreases expression |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
decreases secretion |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
decreases activity |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
decreases expression |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
increases expression |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
multiple interactions |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
decreases expression |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
decreases expression |
EXP |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
multiple interactions |
EXP |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Xiap |
X-linked inhibitor of apoptosis |
|
decreases expression |
ISO |
X |
3,011,520 |
3,047,798 |
RGD:6480464 |
CTD |
Term paths to the root
|